Delaware Biomarker Testing Bill Heads to Governor After Legislative Approval
核心洞察
Delaware's SB120, requiring insurance companies to cover biomarker testing, has passed the General Assembly and now awaits Governor Matthew Meyer's signature.
Biomarker testing identifies unique cancer characteristics, enabling oncologists to match patients with personalized treatments that improve outcomes and reduce unnecessary side effects.
A patient diagnosed with colorectal cancer (搜索) at age 23 credits biomarker testing and subsequent targeted therapy (搜索) with helping achieve remission.
Delaware is poised to expand access to biomarker testing for cancer patients after legislation requiring insurance coverage passed the General Assembly and advanced to Governor Matthew Meyer's desk for signature. The measure, identified as SS1 for SB120, mandates that insurance companies cover biomarker testing, a step advocates describe as a critical milestone for individuals living with cancer in the state.
Darcy Burbage, an Oncology Clinical Nurse Specialist, announced the legislative approval, stating, "We did it! SS1 for SB120 requiring insurance companies to cover biomarker testing has passed the Delaware General Assembly and is heading to Governor Matthew Meyer's desk for his signature!"
The Role of Biomarker Testing in Cancer Care
Biomarker testing analyzes a patient's unique disease to develop personalized treatment plans. According to Burbage, "Biomarker testing is a critical component of modern cancer care as it helps identify the unique characteristics of an individual's cancer so that oncologists can match patients with the most effective, personalized treatments for them as each person's cancer has a unique pattern of biomarkers."
This targeted approach improves outcomes, reduces unnecessary side effects, and avoids ineffective therapies. Access to this precision medicine has helped improve outcomes and quality of life for cancer patients, and it is considered critical to the treatment of many other diseases as well.
A Patient's Perspective
The clinical significance of biomarker testing is underscored by patient testimony. One individual diagnosed with colorectal cancer (搜索) in 2017 at age 23 described how, by the time the cancer was detected, it had already spread to the lungs. The patient underwent biomarker testing in 2021, four years after the initial diagnosis.
"Had I received the testing at the outset, I could have avoided additional, unnecessary treatments and complications," the patient wrote. "When I ultimately received biomarker testing, the results indicated that I would benefit from a targeted therapy (搜索) to which I credit my remission."
The patient, currently in remission, noted that cancer has been kept at bay "in part, because of biomarker testing."
Addressing an Access Gap
Despite the demonstrated benefits, not all patients in Delaware have been able to access biomarker testing because insurance coverage has not kept pace with scientific evidence. The legislation aims to close this gap by improving coverage of necessary biomarker testing for patients insured by state-regulated health plans, including Medicaid.
The House recently passed the legislation, and it now sits before Governor Matt Meyer, whom advocates describe as "a champion of biomarker testing access."
Burbage framed the development as a collaborative achievement, stating, "This is an exciting milestone for individuals living with cancer in Delaware and a powerful reminder of what can be accomplished when patients, healthcare professionals, advocates, organizations, and policymakers work together!"
She extended congratulations and thanks to "the advocates that shared their stories, provided testimony, the organizations that submitted letters of support, and the elected officials who championed this important legislation!"